Reduction in angiogenesis after neoadjuvant chemoendocrine therapy in patients with operable breast carcinoma

Cancer

Volumn 85, Issue 9, 1999, Pages 1996-2000

  Makris, Andreas ^a,d   Powles, Trevor J ^a   Kakolyris, Stelios ^b   Dowsett, Mitch ^c   Ashley, Sue E ^a   Harris, Adrian L ^b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

Angiogenesis; Breast carcinoma; Chemotherapy; Neoadjuvant; Tamoxifen

Indexed keywords

METHOTREXATE; MITOMYCIN C; MITOXANTRONE; TAMOXIFEN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER REGRESSION; CLINICAL TRIAL; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; TUMOR VASCULARIZATION;

EID: 0033135806     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990501)85:9<1996::AID-CNCR17>3.0.CO;2-H     Document Type: Article

References (17)

1. Folkman J. What is the evidence that tumours are angiogenesis dependent. J Natl Cancer Inst 1990;82:4-6.
2. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
3. Fox SB, Leek RD, Bliss J, Mansi JL, Gusterson B, Gatter KC, et al. Association of tumor angiogenesis with bone marrow micrometastases in breast cancer patients. J Natl Cancer Inst 1997;89:1044-9.
4. Bosari S, Lee AKC, DeLellis RA, Wiley BD, Heatley GJ, Silverman ML. Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol 1992;23:755-61.
5. Gasparini G, Fox SB, Verderio P, Bonoldi E, Bevilacqua P, Dante S, et al. Determination of angiogenesis adds information to estrogen receptor status in predicting the efficacy of adjuvant tamoxifen in node-positive breast cancer patients. Clin Cancer Res 1996;2:1191-8.
6. Bicknell R. Vascular targeting and the inhibition of angiogenesis. Ann Oncol 1994;5:45-50.
7. Harris AL, Fox S, Bicknell R, Leek R, Relf M, LeJeune S, et al. Gene therapy through signal transduction pathways and angiogenic growth factors as therapeutic targets in breast cancer. Cancer 1994;74:1021-5.
8. Oktaba AMC, Hunter WL, Aresenault AL. Taxol: a potent inhibitor of normal and tumor-induced angiogenesis [abstract 2707]. Proc Am Assoc Cancer Res 1995;36: 454.
9. Belotti D, Nicoletti I, Vergani V, Rieppi M, Drudis T, Viale G, et al. Paclitaxel (Taxol), a microtubule affecting drug, inhibits tumour induced angiogenesis [abstract 397]. Proc Am Assoc Cancer Res 1996;37:57.
10. Kato T, Sato K, Kakinuma H, Matsuda Y. Enhanced suppression of tumor growth by combination of angiogenesis inhibitor o-(chloroacetyl-carbamoyl) fumagillol (TNP-470) and cytotoxic agents in mice. Cancer Res 1994;54:5143-7.
11. Lindner DJ, Borden EC. Effects of tamoxifen and interferon-beta or the combination on tumor-induced angiogenesis. Int J Cancer 1997;71:456-61.
12. Powles TJ, Hickish TF, Makris A, Ashley SE, O'Brien MER, Tidy VA, et al. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 1995;13:547-52.
13. Hayward JL, Carbone PP, Heuson JC, Kumaoka S, Segaloff A, Rubens RD. Assessment of response to therapy in advanced breast cancer. Br J Cancer 1977;35:292-8.
14. Fox SB, Turner GDH, Leek RD, Whitehouse RM, Gatter KC, Harris AL. The prognostic value of quantitative angiogenesis in breast cancer and the role of adhesion molecule expression in tumor endothelium. Breast Cancer Res Treat 1995; 36:219-26.
15. Folkman J. Antiangiogenic therapy. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. Philadelphia: Lippincott-Raven Publishers, 1997: 3075-85.
16. Teicher BA, Holden SA, Gulshan A, Alvarez Sotomayer E, Huang ZD, Chen Y, et al. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other antiangiogenic agents. Int J Cancer 1994;57:920-25.
17. Martin L, Holcombe C, Green B, Leinster SJ, Winstanley J. Is a histological section representative of whole tumour vascularity in breast cancer? Br J Cancer 1997;76:40-3.